TytoCare Raised $25M to Bring the Physical Exam Into the Home

TytoCare raised more than $25 million on July 15, 2026, to expand technology that lets clinicians examine a patient's heart, lungs, ears, skin, throat, and abdomen from a distance.[1]

The company is addressing a basic limitation of virtual care. A conventional video visit lets a doctor see and speak with you. It usually does not let the doctor listen for a wheeze, inspect your eardrum, or record your heart sounds. TytoCare combines those exam tools in a handheld device that a patient or caregiver can use at home while a clinician guides the visit.[1][2]

The new funding will support more artificial intelligence (AI) analysis, additional health-system partnerships, and programs for cardiopulmonary disease, cancer care, and recovery after surgery. TytoCare also named Adam Pellegrini as chief executive officer and Greg Orr as chief operating officer.[1]

This is a practical extension of telehealth. It also has firm limits. The device cannot palpate an abdomen, order an X-ray, draw blood, or replace an in-person examination when a clinician needs one.

What TytoCare Actually Does

TytoCare builds a handheld medical-exam kit for patients, caregivers, and clinical staff. The device connects to a phone or tablet and sends exam recordings to a clinician during a live visit or for later review.[2]

The attachments let a clinician collect several kinds of information remotely:

• Heart and lung sounds: A digital stethoscope records sounds that the clinician can hear remotely.

• Ear images: An otoscope attachment captures the ear canal and eardrum.

• Throat images: A tongue-depressor attachment helps the camera see the mouth and throat.

• Skin images: The camera can capture a rash or other visible finding.

• Temperature and abdominal sounds: The kit can record temperature and transmit sounds from the abdomen.[1][2]

TytoCare also sells AI software that analyzes certain recordings. The US Food and Drug Administration (FDA) has cleared its software that flags suspected wheezing in a lung-sound recording. The agency separately granted a De Novo classification to software that analyzes eardrum images for bulging.[7][8] These outputs support a clinician's judgment. The FDA states that a licensed healthcare professional must interpret the lung-analysis result and consider it with the recording and the patient's other information.[7]

That distinction matters. TytoCare supplies the exam data and decision support. A clinician still decides what the finding means, whether treatment is appropriate, and whether the patient needs in-person care.

Who Built TytoCare

Dedi Gilad and Ofer Tzadik founded TytoCare in Israel in 2012.[3] Gilad had worked in engineering, research and development, and healthcare technology. Tzadik had worked in healthcare information technology, semiconductors, communications, and operations.[3]

The original idea came from Gilad's experience taking his young daughter to repeated appointments for ear infections. He wanted a clinician to examine her ear without requiring another trip to a clinic, so he began working on a device that could transmit the relevant exam from home.[4]

Gilad led TytoCare for 13 years and now serves on its board. Tzadik remains a co-founder, and the company lists him on its current leadership page.[3] Pellegrini, the new chief executive, previously ran Kaia Health through its acquisition by Sword Health. His earlier roles included Fitbit, CVS Health, and Walgreens Boots Alliance.[3]

TytoCare has financed its growth through repeated venture rounds and commercial partnerships. A $50 million Series D extension in 2021 brought its disclosed funding to $155 million.[5] The company raised another $49 million in 2023, led by Insight Partners, and reported $205 million in total funding at that point.[6] Adding the new round brings TytoCare's publicly announced capital to more than $230 million.

What the New $25M Round Is Financing

Insight Partners led TytoCare's $49 million round in 2023 and led this one at roughly half the size, alongside a handoff from founder Dedi Gilad to Adam Pellegrini, an operator whose background runs through CVS Health, Walgreens, and a completed acquisition at Kaia Health.

Given the round size the $25m is likely a bridge round into a larger stage of financing along with some shifts in management. This is normally the case when a company has previously raised larger rounds in the past, but the current round is designed to trade a small portion of equity to get them on to the next round of funding.

TytoCare says the money will support three areas:[1]

1. More AI algorithms. The company plans to expand software that evaluates the sounds and images collected by its devices.

2. More health-system and payer integrations. TytoCare sells through healthcare organizations that connect the device with their clinicians and records.

3. More complex use cases. The company is moving beyond occasional primary-care visits into congestive heart failure, chronic obstructive pulmonary disease (COPD), cancer-treatment support, and post-surgical recovery.

The third item is the consequential one. A parent using the device once for a child's ear pain is an episodic use. A patient with COPD recording lung sounds during repeated follow-ups creates an ongoing clinical workflow. That requires reliable training, consistent recordings, clinician capacity, escalation rules, and integration with the patient's medical record.

TytoCare has already taken steps in that direction. In 2024, it partnered with Frontier Health to include the device in a virtual extension of a direct primary care program.[12] In November 2025, TytoCare announced an integration with Teladoc Health's Primary360 and 24/7 Care programs, with rollout planned during 2026.[13]

The new funding gives the company more time to prove that the hardware and software work inside those continuing-care programs, rather than only during one-off virtual visits.

What the Clinical Evidence Shows

The available clinical evidence answers narrower questions than the funding announcement suggests.

A 2023 nonrandomized controlled trial in JAMA Network Open compared TytoCare-assisted remote examinations with conventional in-person examinations in 690 pediatric patients at two hospitals in Brazil. The study found satisfactory agreement for ear, throat, skin, heart, and lung findings in children older than two. It also found limitations for heart and lung sounds in infants and abdominal sounds across age groups.[9]

The detailed results varied by exam. Agreement reached 94% for rash, 95% for heart murmurs, and 91% for abnormal lung sounds. Agreement was lower for the ear canal at 72% and throat or oral examination at 72%.[9] The study supports use in selected pediatric settings. It does not establish that every home exam matches an in-person visit or that the device can safely handle every symptom.

The FDA record for TytoCare's wheeze-detection software offers another useful boundary. The submitted data showed 54.7% sensitivity and 99.0% specificity for one version of the software. Sensitivity describes how often the software identified recordings with the target finding. Specificity describes how often it correctly treated recordings without the finding as negative.[7]

High specificity can help reduce false alarms. Lower sensitivity means the software can miss some true wheezes. The FDA instructions therefore require professional interpretation and state that the result must be considered alongside the recording and other patient data.[7]

A separate economic study in the Journal of Health Economics compared people who adopted a home exam device with matched patients who used the same virtual clinic without one. Device adoption was associated with 12% more primary-care use and lower use of urgent care, emergency departments, and hospital care, particularly among adults. Total healthcare costs did not increase in the study's main summary.[10]

That observational analysis of actual healthcare use differs from a randomized clinical trial. People who adopted the device may differ from those who did not. The results support further use and study, but they do not prove that the device alone caused every difference.

The Home Exam Still Has Practical Limits

The device's usefulness depends on more than FDA status and sensor accuracy. It also depends on whether a patient can connect it, position each attachment correctly, and send a usable recording.

A pilot involving 43 caregivers of children with complex medical needs found that caregivers rated TytoCare's usability highly. Providers gave it a lower usability score. Technology problems caused 15% of 83 practice encounters to be cancelled or end early.[11]

That study was small, but the operational lesson is important. A remote stethoscope creates value only when the recording reaches a clinician in a form that the clinician can use.

TytoCare also leaves several parts of the physical exam at the clinic:

• A doctor cannot press on a painful abdomen through the device.

• The device does not produce a chest X-ray, electrocardiogram, blood test, or ultrasound.

• A home recording can be incomplete or poorly positioned.

• AI analysis covers specific cleared tasks, rather than every condition involving the ears, lungs, heart, throat, skin, or abdomen.

• A clinician may still direct the patient to an office, urgent-care center, or emergency department after reviewing the exam.

Readers can review NextMD's guide to what “FDA cleared” means for a health product for more detail on the difference between clearance, approval, authorization, and general wellness claims.

Where TytoCare Fits With Concierge and Direct Primary Care

TytoCare becomes more useful when the remote clinician already knows the patient.

Consider a seven-year-old with a temperature of 101.8 degrees and new ear pain. A remote doctor can use TytoCare to inspect the eardrum. The parent still needs a clinician who knows the child's allergies, recent antibiotic use, prior ear infections, and local options if an in-person examination becomes necessary.

The same principle applies to chronic care. A patient can transmit a new lung recording. The treating doctor still needs the medication list, prior lung function, recent symptoms, and an escalation plan.

Concierge and direct primary care (DPC) practices already build around continuing access to a physician. NextMD's directory benchmarks put concierge panels under 300 patients per doctor and DPC panels up to 800. Those smaller panels give the physician more capacity to review a remote finding, compare it with the patient's history, and decide what happens next. NextMD's primary-care model comparison explains how those relationships differ from transactional urgent care and conventional telehealth.

For a technology-focused concierge practice such as Sigma Humans in Chicago, a home exam device could add objective information to an after-hours call or a travel visit. That is an inferred use case. Sigma Humans has not stated that it currently uses TytoCare.

The device can also complement house calls. A practice may reserve an in-person visit for the situations that require hands-on assessment while handling a narrower ear, throat, skin, or lung follow-up remotely. Our guide to house-call doctors covers the higher-touch end of that same care model.

What Patients Should Ask Before Using It

Access and pricing vary by health plan and clinical partner. A St. Luke's Health Plan partnership announced a $0 virtual-visit copay for eligible members, while a Northwestern Medicine program lists a $99 device price for eligible patients.[14][15] Your cost, available clinicians, and supported services will depend on the organization providing the program.

Ask these questions before relying on the device:

1. Who reviews my exam? Confirm whether the recording goes to your regular doctor, a health-system clinician, or an on-demand virtual-care group.

2. How quickly will someone respond? Ask separately about routine recordings, same-day illness, nights, and weekends.

3. Which findings can the AI analyze? Request the specific FDA-cleared uses. Do not treat a general AI label as coverage for every exam.

4. What happens when the recording is unclear? Ask whether staff will help you repeat it and when they will direct you to in-person care.

5. Does the exam enter my medical record? A remote finding is more useful when your other clinicians can see it.

6. What will I pay? Separate the device price, virtual-visit charge, insurance copay, and any subscription fee.

7. What is the emergency plan? The device should sit inside a clear clinical pathway, including instructions for symptoms that require immediate in-person care.

The Bottom Line

TytoCare has raised more than $230 million in disclosed funding to make virtual care more clinically informative. Its handheld kit gives remote clinicians access to heart and lung sounds, ear and throat images, skin images, temperature, and abdominal sounds. Its FDA-cleared wheeze software and De Novo-classified eardrum tool can assist with specific findings.[1][5][6][7][8]

The evidence supports selected uses. A 690-patient pediatric study found useful agreement with in-person examinations in several areas, while also documenting weaker performance in others.[9] A smaller implementation study showed that training and connectivity can determine whether the exam happens at all.[11]

For concierge and DPC care, the opportunity is straightforward. The device can extend a physician relationship into the home. The physician relationship supplies the history, judgment, follow-up, and local escalation path that the hardware cannot provide.

FAQ

How much did TytoCare raise in 2026?

TytoCare announced a growth round of more than $25 million on July 15, 2026. Insight Partners led the financing, with participation from Healthcare of Ontario Pension Plan, OliveTree, OrbiMed, Qumra Capital, Qualcomm Ventures, and other investors.[1]

What does a TytoCare device examine?

TytoCare can transmit heart and lung sounds, images of the ears, throat, and skin, body temperature, and abdominal sounds to a remote clinician. The device works through attachments that a patient, caregiver, or clinical staff member positions during the exam.[1][2]

Can TytoCare diagnose a patient without a doctor?

No. TytoCare's AI can analyze certain recordings for specific cleared uses, but a licensed healthcare professional must interpret the output with the recording and other patient information.[7][8]

Is TytoCare FDA-approved?

TytoCare has FDA-cleared devices and algorithms, plus a De Novo classification for its eardrum-bulging analysis. Those decisions apply to defined uses. They do not represent approval of every possible home diagnosis or the entire service as a substitute for in-person care.[7][8]

Does TytoCare replace an in-person physical exam?

No. It can extend parts of the exam into the home, including digital auscultation and ear or throat imaging. It cannot perform palpation, laboratory testing, X-rays, ultrasound, or every other part of an in-person assessment.

How much does TytoCare cost?

The price depends on the health plan, employer, or health system offering it. Some eligible patients receive a device at no cost, while other partner programs charge for the kit and bill the associated virtual visit under their own terms.[14][15]

Find a Doctor Who Can Use the Information

A home exam device is more useful when a physician knows your history and remains responsible for follow-up. NextMD is a free directory of physician-led concierge and direct primary care practices across the United States. Search by city and compare practices to find a doctor who can combine remote information with continuing care.

Sources

1. TytoCare. (2026, July 15). TytoCare Names Adam Pellegrini as CEO and Closes $25M+ Growth Round to Scale AI-First Clinical Enablement Platform. Read the funding announcement

2. TytoCare. (2026). TytoHome: How a TytoCare Visit Works. View the consumer product page

3. TytoCare. (2026). About Us. View the leadership biographies

4. TytoCare. (2018). Tyto Care Brings the Doctor's Visit to Home: Interview With Ophir Lotan. Read the origin story

5. TytoCare. (2021, March 4). TytoCare Extends Series D Funding With Additional $50M. Read the Series D announcement

6. TytoCare. (2023, August 3). TytoCare Announces $49 Million Funding Round and Launches New Care Modules. Read the 2023 funding announcement

7. US Food and Drug Administration. (2023, December 13). 510(k) Summary K232237: Tyto Insights for Wheeze Detection. Read the FDA summary

8. US Food and Drug Administration. (2026, March 17). De Novo Classification Request DEN250014: Tyto Insights for Eardrum Bulging Detection. Read the FDA summary

9. Wagner, R., Lima, T. C., Silva, M. R. T., et al. (2023). Assessment of Pediatric Telemedicine Using Remote Physical Examinations With a Mobile Medical Device: A Nonrandomized Controlled Trial. JAMA Network Open, 6(2), e2252570. Read in JAMA Network Open

10. Zeltzer, D., Einav, L., Rashba, J., Waisman, Y., Haimi, M., & Balicer, R. D. (2023). Adoption and Utilization of Device-Assisted Telemedicine. Journal of Health Economics, 90, 102780. Read the study PDF

11. Sibilia, A. J., Callahan, S. R., Pulda, K., et al. (2024). Usability and Feasibility of an In-Home Remote Exam Device in Children With Medical Complexity During the COVID-19 Pandemic. Telemedicine and e-Health. Read on PubMed Central

12. TytoCare. (2024, October 14). TytoCare and Frontier Health Partner to Provide Virtual-First Primary Care. Read the direct-primary-care partnership announcement

13. TytoCare. (2025, November 18). TytoCare Integrates With Teladoc Health to Augment Virtual Primary and Urgent Care. Read the integration announcement

14. TytoCare and St. Luke's Health System. (2023, November 29). Exclusive Partnership to Bring Virtual Primary Care to Idaho. Read the partnership announcement

15. Northwestern Medicine and TytoCare. (2026). TytoCare for Northwestern Medicine Immediate Care. View program eligibility and pricing

Source Attribution

• Funding amount, investors, planned uses, and executive appointments come from TytoCare's July 15 announcement.

• The disclosed funding total is calculated from company-announced totals and the new round. TytoCare did not publish an updated cumulative figure in the July announcement.

• Clinical-performance claims are limited to the cited FDA records and peer-reviewed studies.

• The article distinguishes company plans for chronic and complex care from evidence already published for specific devices and settings.

Review Notes

• Company and founder history, prior rounds, FDA status, clinical evidence, and consumer access were checked against the cited sources on 2026-07-19.

• Internal links include three related NextMD articles, the Chicago city page, and one physician-led practice page.

• The Sigma Humans example is explicitly labeled as an inferred use case. The article does not claim the practice uses TytoCare.

• Editorial gate passed on 2026-07-19: 2,448-word body against a 2,400 target, zero em dashes, five internal links, and 15 external source links. The link checker returned zero failures and one expected bot-block warning for JAMA Network Open.